In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…
FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
WASHINGTON (Reuters)—U.S. Food and Drug Administration chief, Scott Gottlieb, criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for “Kabuki drug-pricing constructs” that profit the industry at the expense of consumers. The comments, made at a conference organized by a leading U.S. health insurer lobbying group, stoked speculation over what steps the administration of…
Opioids No Better Than NSAIDs for Chronic Back or Arthritis Pain
(Reuters Health)—Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests. And opioids are no better than these other drugs at reducing how much pain interferes with daily activities, such as walking, working, sleeping or enjoying…
FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval
After reviewing a 10-year study, the FDA cautions that prescribing clarithromycin to patients with heart disease increases the risk of heart problems or death…
Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
NEW YORK (Reuters Health)—Diclofenac patches appear to be the most effective topical nonsteroidal anti-inflammatory drug (NSAID) for osteoarthritis (OA), according to a new systematic review and network meta-analysis. “Topical NSAIDs were effective and safe for OA,” Dr. Weiya Zhang of the University of Nottingham and City Hospital in the UK and colleagues write. “However, confirmation…
The Science Behind Biosimilars
Although six biosimilar agents have now been approved by the U.S. Food & Drug Administration for use in rheumatology, scientific, clinical, economic and prescribing questions about the use of biosimilars abound. In fact, at the 2017 ACR/ARHP Annual Meeting in San Diego, Joseph Huffstutter, MD, a rheumatologist in private practice in Chattanooga, Tenn., said that…
What’s Driving the Pain? Alternative Approaches to Pain Management
Patients can experience many different types of pain, and some patients with chronic pain may believe that only opioids will help them. According to Kelly Weselman, MD, the best way to begin managing pain is to determine its root cause and communicate with the patient about the best approach(es) for decreasing their specific pain…
Baricitinib Also Appears Effective in Biologic-Refractory RA
NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial. The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical…
Ferumoxytol Injection Receives New Indication, & Application for GP2017 Moves Ahead
The FDA recently expanded the indications for ferumoxytol injections to include the treatment of adults with iron-deficiency anemia…
Balancing Opioid Addiction Risk with Pain Management Needs
SAN DIEGO—During a session at the ACR/ARHP 2017 Annual Meeting Nov. 3–8, three representatives from the federal government described several of the government’s varied national strategies and agencies that are tackling pain. All of these strategies are affected by the current national epidemic of opioid overdoses and the need for safer analgesic prescribing. But the…
- « Previous Page
- 1
- …
- 55
- 56
- 57
- 58
- 59
- …
- 126
- Next Page »